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The optimal treatment of asymptomatic brain metastases (BMs) in non–small-cell lung cancer (NSCLC) patients 
is still controversial. The role of upfront chemotherapy has 
not been extensively investigated in randomized clinical trials, 
mainly because of the belief that blood–brain barrier (BBB) 
would limit the delivery of cytotoxic drugs. However, plati-
num-based chemotherapy has reported intracranial response 
rates ranging from 30% to 45%.1,2 This finding is probably 
related to the disruption of the BBB in the presence of BMs 
with consequent penetration of antineoplastic drugs in the 
tumor tissue. 18F-sodium fluoride (18F-NaF) is a radiophar-
maceutical widely used for positron emission tomography–
computed tomography (PET–CT) bone scan to detect skeletal 
metastases. Some cases of unexpected 18F-NaF uptake within 
BMs from lung cancer, breast cancer, and melanoma have 
been observed.3,4 Furthermore, our research group has recently 
reported a case series of nine patients with known BMs from 
different primary tumors, whose intracranial metastases were 
detectable by 18F-NaF PET-CT.5 Here, we report a case of 
a patient with metastatic non–small-cell lung cancer and a 
single BM treated with upfront chemotherapy, who underwent 
18F NaF PET-CT before and after systemic treatment.
CASE REPORT
A 57-year-old female former smoker presented with 
dry cough and chest pain. She had a chest CT scan which 
demonstrated a 7 cm right upper lobe mass invading medi-
astinum and anonymous vein. The patient underwent endo-
bronchial ultrasound-guided trans-tracheal needle aspiration 
of the pulmonary lesion, and pathology examination showed 
lung adenocarcinoma, with wild-type EGFR and nontranslo-
cated ALK. Abdomen CT scan was negative, whereas head 
CT scan and MRI showed a 1.2 cm BM in right parietal lobe 
with surrounding edema (Fig. 1A). The patient had a 18F-NaF 
PET–CT which showed a lytic metastasis in left iliac bone, 
and also revealed a 18F-NaF uptake of the BM with SUV
max
 
4.2 (Fig. 1B, C). The patient was started on chemotherapy 
with cisplatin (75 mg/m2) and pemetrexed (500 mg/m2) every 
3 weeks. The brain MRI performed after two cycles showed 
a reduction of the BM to 0.9 cm, and the 18F-NaF PET–CT 
demonstrated a decrease of SUV
max
 to 2.40 (Fig. 2).
DISCUSSION
This report suggests that in selected patients upfront 
chemotherapy may achieve an intracranial response. The 
18F-NaF uptake of BM has been already reported by other 
authors.3,4 In our patient, consistently with the objective 
response assessed by MRI, the 18F-NaF SUV decreased of 
about 50% after two cycles of chemotherapy. However, it is 
unknown if 18F-NaF is able to provide an estimation of the 
entity of BBB damage and, moreover, if such damage would 
be predictive for response of BMs to systemic or local ther-
apy. Accordingly, a prospective clinical trial to investigate the 
potential role of 18F-NaF PET–CT as a predictive tool for 
patients with BMs is planned.
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FIGURE 2.  Imaging of brain metastasis after two cycles of cisplatin and pemetrexed. A, Brain MRI showing right parietal 
metastasis, decreased in size when compared with baseline (9 vs 12 mm, see Fig. 1). B, 18F-NaF PET-CT performed 5 minutes 
after tracer injection; the uptake intensity of brain metastasis has decreased from baseline: SUVmax from 4.20 to 2.40 (see Fig. 1). 
C, 18F-NaF PET-CT 30 minutes after tracer injection. MRI, magnetic resonance imaging; NaF, sodium fluoride; PET–CT, positron 
emission tomography–computed tomography.
FIGURE 1.  Imaging of brain metastasis before starting systemic therapy. A, Brain MRI showing 12 mm right parietal metastasis 
with surrounding edema. B, 18F-NaF PET-CT with right parietal brain metastasis uptake 5 minutes after tracer injection; at that 
time, 18F-NaF is also detectable in the bloodstream within dural venous sinuses. C, 18F-NaF PET-CT 30 minutes after tracer 
injection; at that time, 18F-NaF is mainly uptaken by cranial bones, but residual uptake of brain metastasis is still detectable. 
MRI, magnetic resonance imaging; NaF, sodium fluoride; PET–CT, positron emission tomography–computed tomography.
